Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAF312 interaction study with a monophasic oral contraceptive in healthy women
NL-OMON37415Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of siponimod, ethinyl estradiol and avatrombopag in multiple sclerosis (MS), sponsored by Novartis. Primary endpoint: Effect of BAF312 on oral contraceptive exposure. Started Feb 2012; status: active, not recruiting.
02
Drugs
siponimodethinyl estradiolavatrombopag
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON37415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37415.